Global IVF (in-vitro fertilization) Market Outlook, 2029

The Global IVF market  is segmented into  By cycle (Fresh Non-donor IVF Cycle , Frozen  Non-donor IVF Cycle , Frozen Donor IVF Cycle , Fresh Donor IVF Cycle) , By Conentional IVF , Conentional IVF , IVF with ICSI (Instracytoplasmic Sperm Injection), IVF with Donor Eggs, other By end users: fertility clinics, hospitals and surgical centers, cryobanks, research institutes).

The Global In vitro fertilization (IVF) Market is anticipated to cross USD 35 Billion by 2029, increasing from USD 24.87 Billion in 2023 with 8.36% CAGR by 2024-29.

IVF (in-vitro fertilization) Market Analysis

In vitro fertilization (IVF) has revolutionized the field of reproductive medicine since its inception in the late 1970s. Originally developed to help couples struggling with infertility, IVF has now become a cornerstone of assisted reproductive technology (ART) and is utilized by individuals and couples worldwide. The IVF industry has grown significantly over the years, driven by advancements in technology, changing societal attitudes towards family planning, and increasing demand for fertility treatments. The journey of IVF from experimental procedure to mainstream fertility treatment has been remarkable. The pioneering work of researchers such as Dr. Robert Edwards and Dr. Patrick Steptoe laid the foundation for the first successful IVF birth with the arrival of Louise Brown in 1978. Since then, the field has witnessed exponential growth, with continuous refinements in laboratory techniques, hormonal stimulation protocols, and embryo transfer procedures. These are specialized medical facilities that offer a range of fertility treatments, including IVF. The quality of care and success rates vary widely among clinics, with some of the leading ones based in the United States, Europe, and Asia. On the other hand, pharmaceutical companies play a crucial role in the IVF industry by developing and manufacturing fertility drugs, such as gonadotropins and antagonists, which are essential for the IVF process. Some of the major players in this sector include Merck, Ferring Pharmaceuticals, and EMD Serono. Factors like delayed childbearing, environmental toxins, and certain medical conditions can contribute to infertility. Additionally, growing awareness and acceptance of IVF treatments are leading more couples to explore this option. The early fee-for-service model for infertility treatments has given way to highly integrated, multicenter corporate businesses driven by profits rather than academic pursuits. This change is reflected in the employment patterns of reproductive endocrinology and infertility (REI) fellows, with only 26% of those trained between 1996 and 2021 currently employed in academic practices. The increasing involvement of private equity in healthcare, particularly in the acquisition of physician practices and hospitals, has led to concerns about the potential detrimental effects on patient care and the academic base of infertility programs. According to the research report, “Global In vitro fertilization (IVF) Market Outlook, 2029” published by Bonafide Research, the market is anticipated to cross USD 35 Billion by 2029, increasing from USD 24.87 Billion in 2023. The market is expected to grow with 8.36% CAGR by 2024-29. Advancements in IVF technology have significantly improved success rates and expanded the scope of treatment options. Innovations such as intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and vitrification of embryos have enhanced the efficacy and safety of IVF procedures. Moreover, the advent of time-lapse imaging systems and artificial intelligence (AI) applications has enabled embryologists to monitor embryo development more closely and select the most viable embryos for transfer, thereby optimizing outcomes. The rapid evolution of IVF technology has raised complex ethical dilemmas regarding reproductive autonomy, embryo disposition, and the commodification of human gametes and embryos. Debates surrounding the use of preimplantation genetic screening for non-medical purposes, the creation and fate of surplus embryos, and the ethical implications of reproductive cloning and germline editing continue to provoke discussions within the scientific community and society at large. Ethical guidelines and professional standards play a crucial role in ensuring that IVF practices uphold principles of beneficence, non-maleficence, and respect for autonomy. The IVF industry is continually evolving, with new technologies and techniques being developed to improve success rates and patient care. These include preimplantation genetic testing (PGT), time-lapse imaging, and artificial intelligence (AI) for embryo selection. The phenomenon of fertility tourism, where individuals travel to other countries for fertility treatments, has been gaining momentum. This is often due to more affordable treatment costs, less restrictive laws, or higher quality of care in the destination country.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Market Dynamic

style="color:orange">Market DriversAdvancements in Technology: Technological innovations have been a primary driver of growth in the IVF industry. Continuous advancements in laboratory techniques, such as embryo culture systems, time-lapse imaging, and genetic screening technologies, have significantly improved success rates and expanded the scope of treatment options for patients. These innovations allow embryologists to select the healthiest embryos for transfer, thereby increasing the chances of successful pregnancies. • Changing Demographics and Societal Trends: Shifting societal attitudes towards family planning and changing demographics have fueled the demand for IVF services. Factors such as delayed childbearing, increasing prevalence of infertility due to lifestyle factors, and the growing acceptance of alternative family structures, including single-parent and same-sex families, have contributed to the rising demand for fertility treatments. Additionally, the global trend of urbanization and the associated lifestyle changes, such as increased stress and environmental factors, have also impacted fertility rates, leading more individuals and couples to seek assistance from fertility clinics. style="color:orange">Market ChallengesAccessibility and Affordability: One of the primary challenges facing the IVF industry is the accessibility and affordability of treatment. IVF procedures can be prohibitively expensive for many individuals and couples, especially in countries where fertility treatments are not covered by insurance or public healthcare systems. The high cost of IVF can create inequities in access to treatment, disproportionately affecting socioeconomically disadvantaged populations. • Ethical and Legal Considerations: The rapid advancements in IVF technology have raised complex ethical and legal dilemmas regarding reproductive autonomy, embryo disposition, and the moral status of embryos. Debates surrounding issues such as the creation and fate of surplus embryos, the use of genetic screening for non-medical purposes, and the regulation of assisted reproductive technologies vary widely across jurisdictions. style="color:orange">Market TrendsPersonalized Medicine and Genetic Screening: A significant trend in the IVF industry is the increasing adoption of personalized medicine approaches, including genetic screening and testing. Preimplantation genetic testing (PGT) allows embryologists to screen embryos for chromosomal abnormalities and genetic disorders before transfer, reducing the risk of miscarriage and improving pregnancy outcomes. As technology continues to advance, the scope of genetic screening in IVF may expand to include polygenic risk scores and other predictive tools for optimizing embryo selection. • Digital Health Solutions and Telemedicine: The COVID-19 pandemic accelerated the adoption of digital health solutions and telemedicine in the IVF industry. Fertility clinics have increasingly embraced teleconsultations, remote monitoring, and digital platforms for patient education and support. These technological innovations not only enhance convenience and accessibility for patients but also enable fertility clinics to streamline operations and improve efficiency in delivering care.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant


IVF (in-vitro fertilization) Segmentation

By Cycle Fresh Non-donor IVF Cycle
Frozen Non-donor IVF Cycle
Frozen donor IVF Cycle
Fresh donor IVF Cycle
By Conentional IVF Conentional IVF
IVF with ICSI (Instracytoplasmic Sperm Injection)
IVF With Donor Eqqs
Others
By End User Fertility Clinics
Hospital & Surgical Centers
Cryobanks
Research institute
By Product Type Equipment
Reagents & Media
Accessories
GeographyNorth AmericaUnited States
Canada
Mexico
EuropeGermany
United Kingdom
France
Italy
Spain
Russia
Asia-PacificChina
Japan
India
Australia
South Korea
South AmericaBrazil
Argentina
Colombia
MEAUnited Arab Emirates
Saudi Arabia
South Africa

Fresh non-donor IVF cycles are leading in the IVF market due to higher success rates and the potential for a larger number of viable embryos. Fresh non-donor IVF cycles are leading in the IVF market primarily due to their higher success rates and the potential for a larger number of viable embryos, making them the preferred choice for many individuals or couples undergoing fertility treatment. The success rates of IVF cycles are largely influenced by the quality of the eggs used, and fresh cycles offer the advantage of utilizing the woman's own eggs. This is particularly significant because the quality of a woman's eggs tends to decline with age, and using younger, healthier eggs can result in higher success rates. In a fresh non-donor IVF cycle, the woman undergoes ovarian stimulation to produce multiple eggs, which are then retrieved and fertilized with sperm in a laboratory. The resulting embryos are cultured for a few days, and the best-quality embryos are selected for transfer back into the woman's uterus. Since these embryos are derived from the woman's own eggs, they are more likely to be of higher quality and have a greater chance of resulting in a successful pregnancy compared to embryos from donor eggs. Furthermore, fresh cycles often yield a larger number of viable embryos compared to frozen cycles. In frozen embryo transfer (FET) cycles, embryos that are not transferred during the fresh cycle can be cryopreserved for future use. However, the freezing and thawing process can sometimes impact embryo viability, leading to lower success rates compared to fresh cycles. Additionally, not all embryos survive the freeze-thaw process, further limiting the number of viable embryos available for transfer. The combination of higher success rates and the potential for a larger number of viable embryos makes fresh non-donor IVF cycles the preferred choice for many patients and fertility clinics alike. While the process require more intensive monitoring and coordination compared to FET cycles, the promising outcomes and the opportunity to utilize the woman's own eggs often outweigh these challenges. Ultimately, the desire for biological parenthood and the pursuit of the best possible chance of success drive the popularity of fresh non-donor IVF cycles in the competitive landscape of assisted reproductive technologies. Conventional IVF is leading in the IVF market due to its versatility in treating a wide range of infertility issues, offering a comprehensive approach to assisted reproduction. Conventional IVF has established itself as a leading choice in the IVF market owing to its versatility and effectiveness in addressing diverse causes of infertility. Unlike specialized IVF procedures such as ICSI (Intracytoplasmic Sperm Injection) or PGT (Preimplantation Genetic Testing), which target specific fertility challenges, conventional IVF provides a comprehensive approach to assisted reproduction. In a conventional IVF cycle, a woman undergoes ovarian stimulation to produce multiple eggs, which are then retrieved and fertilized with sperm in a laboratory setting. The resulting embryos are cultured for a few days, and the best-quality embryos are selected for transfer back into the woman's uterus. This approach allows for the treatment of various causes of infertility, including male factor infertility, tubal factor infertility, endometriosis, and unexplained infertility. The versatility of conventional IVF makes it suitable for a wide range of patients, regardless of the specific fertility issues they may be facing. For example, couples dealing with male factor infertility, where the sperm may have low motility or morphology, can benefit from conventional IVF as it allows for the selection of the healthiest sperm to fertilize the eggs. Similarly, women with tubal factor infertility, caused by blocked or damaged fallopian tubes, can undergo conventional IVF to bypass the fallopian tubes and achieve fertilization in the laboratory. Additionally, conventional IVF can be used in conjunction with advanced reproductive techniques such as ICSI or PGT if needed, further enhancing its effectiveness in addressing complex fertility challenges. Another factor contributing to the popularity of conventional IVF is its established track record of success. Over several decades, conventional IVF has helped countless couples worldwide achieve their dream of parenthood, providing reassurance to patients and healthcare providers alike. The well-established protocols and procedures associated with conventional IVF contribute to its reliability and efficacy, instilling confidence in both patients and clinicians. Fertility clinics are leading in the IVF market due to their specialized expertise, state-of-the-art facilities, and comprehensive range of services tailored to meet the diverse needs of individuals and couples seeking assisted reproductive technologies. Fertility clinics have emerged as leaders in the IVF market by offering specialized expertise, cutting-edge technology, and a wide array of services designed to address the unique challenges of infertility. These clinics are staffed by highly trained reproductive endocrinologists, embryologists, nurses, and support staff that specialize in the diagnosis and treatment of infertility. Their expertise allows them to provide personalized care and tailored treatment plans to each patient, taking into account their medical history, specific fertility issues, and personal preferences. In addition to their specialized expertise, fertility clinics invest in state-of-the-art facilities and equipment to deliver the highest standard of care to their patients. These clinics are equipped with advanced laboratory facilities for procedures such as egg retrieval, embryo culture, and embryo transfer, ensuring the optimal conditions for the success of IVF procedures. Furthermore, fertility clinics often offer a comprehensive range of services beyond IVF, including diagnostic testing, fertility preservation, donor egg/sperm programs, and third-party reproduction options such as surrogacy, catering to the diverse needs of individuals and couples seeking fertility treatment. The success of fertility clinics in the IVF market is also attributed to their commitment to continuous innovation and research. Clinics regularly update their protocols and techniques based on the latest scientific advancements and clinical evidence, ensuring that patients have access to the most effective and cutting-edge treatment options available. This commitment to innovation, coupled with a patient-centered approach to care, fosters trust and confidence among patients, making fertility clinics the preferred choice for individuals and couples embarking on their fertility journey. Furthermore, fertility clinics prioritize patient support and education, offering counseling services, support groups, and resources to help patients navigate the emotional and psychological aspects of infertility treatment. The compassionate and empathetic approach of fertility clinic staff helps patients feel supported and empowered throughout their fertility journey, fostering a positive patient experience and enhancing overall satisfaction with the care received.

IVF (in-vitro fertilization) Market Regional Insights

Europe is leading in the IVF market due to its favorable regulatory environment, which supports accessibility, affordability, and high-quality standards in assisted reproductive technologies. Europe has established itself as a leader in the IVF market primarily due to its favorable regulatory landscape, which fosters accessibility, affordability, and adherence to high-quality standards in assisted reproductive technologies (ART). Unlike some regions where IVF regulations may be restrictive or subject to significant limitations, Europe has developed a regulatory framework that prioritizes patient safety, ethical considerations, and equitable access to fertility treatment. One key aspect of Europe's regulatory environment is its approach to licensing and accreditation of fertility clinics. Many European countries have robust regulatory bodies or professional organizations overseeing fertility clinics, which set standards for clinical practice, laboratory procedures, and patient care. These standards help ensure that fertility clinics adhere to strict quality control measures, maintain high success rates, and prioritize patient safety throughout the IVF process. Additionally, accreditation programs provide patients with assurance regarding the credibility and reliability of the clinics they choose for their fertility treatment. Moreover, Europe's regulatory environment promotes accessibility and affordability of IVF treatment by offering various forms of public funding or insurance coverage for infertility services. In some European countries, such as the Nordic nations and parts of Western Europe, IVF treatment may be partially or fully subsidized by the government or covered by public health insurance schemes. This financial support reduces the financial burden on patients and enhances accessibility to IVF treatment for a broader segment of the population. Furthermore, Europe's commitment to ethical and responsible use of assisted reproductive technologies has contributed to its leadership in the IVF market. Many European countries have enacted legislation or guidelines addressing ethical issues such as gamete donation, embryo research, and surrogacy, providing a framework for responsible practice and ensuring that fertility treatment is conducted in an ethically sound manner.

Key Development

• June of 2023, the debut of MilliporeSigma's new CellToxTM Assay Platform was announced. The platform consists of a collection of in vitro tests intended to evaluate the safety of substances and medications. • In June 2023, FUJIFILM Irvine Scientific, Inc. expanded its Presagen’s Life Whisperer platform capabilities to help with clinical decision-making in IVF. • WuXi AppTec announced in May 2023 that it’s in vitro toxicological capabilities have expanded. New assays will be included as part of the expansion and a new service for creating personalized in vitro assays will be introduced. • In May 2023, Ovation Fertility combined with US Fertility to created fertility platform offering advanced fertility care and IVF services in the U.S. • In May 2023, Merck KGaA introduced Fertility Counts to address societal, economic, and social challenges associated with low birth rates in the Asia-Pacific (APAC) region. • Thermo Fisher Scientific Inc. said in April 2023 that it had acquired CooperSurgical, an IVF supplier of goods and services. Thermo Fisher will be able to increase its market share in the IVF sector thanks to the acquisition. • In April 2023, Boston IVF signed 3 years supply chain solutions agreement with Cryoport, Inc. to support the reproductive material shipment across the U.S. • Vitrolife declared in March 2023 that the FDA has approved its Cryotop vitrification device. A novel method for vitrifying embryos—a quick freezing procedure used to maintain their viability—is the Cryotop system.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Discount offer

Companies Mentioned

  • The Cooper Companies Inc.
  • DCL Corporation
  • Thermo Fisher Scientific Inc
  • Fujifilm Holdings Corporation
  • Vitrolife AB
  • Esco Micro Pte. Ltd.
  • Genea Limited
  • Ferring Pharmaceuticals
  • Hamilton Thorne Inc.
  • Carl Zeiss AG,
  • Cook Group Incorporated
  • Kitazato Corporation
  • Inser
Company mentioned

Table of Contents

  • 1. Executive Summary
  • 2. Market Dynamics
  • 2.1. Market Drivers & Opportunities
  • 2.2. Market Restraints & Challenges
  • 2.3. Market Trends
  • 2.3.1. XXXX
  • 2.3.2. XXXX
  • 2.3.3. XXXX
  • 2.3.4. XXXX
  • 2.3.5. XXXX
  • 2.4. Covid-19 Effect
  • 2.5. Supply chain Analysis
  • 2.6. Policy & Regulatory Framework
  • 2.7. Industry Experts Views
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Market Structure
  • 4.1. Market Considerate
  • 4.2. Assumptions
  • 4.3. Limitations
  • 4.4. Abbreviations
  • 4.5. Sources
  • 4.6. Definitions
  • 5. Economic /Demographic Snapshot
  • 6. Global In Vitro Fertilization Market Outlook
  • 6.1. Market Size By Value
  • 6.2. Market Share By Region
  • 6.3. Market Size and Forecast, By Geography
  • 6.4. Market Size and Forecast, By Cycle
  • 6.5. Market Size and Forecast, By Conventional IVF
  • 6.6. Market Size and Forecast, By End user
  • 7. North America In Vitro Fertilization Market Outlook
  • 7.1. Market Size By Value
  • 7.2. Market Share By Country
  • 7.3. Market Size and Forecast, By Cycle
  • 7.4. Market Size and Forecast, By Conventional IVF
  • 7.5. Market Size and Forecast, By End user
  • 7.6. United States In Vitro Fertilization Market Outlook
  • 7.6.1. Market Size By Value
  • 7.6.2. Market Size and Forecast By Cycle
  • 7.6.3. Market Size and Forecast By Conventional IVF
  • 7.6.4. Market Size and Forecast By End user
  • 7.7. Canada In Vitro Fertilization Market Outlook
  • 7.7.1. Market Size By Value
  • 7.7.2. Market Size and Forecast By Cycle
  • 7.7.3. Market Size and Forecast By Conventional IVF
  • 7.7.4. Market Size and Forecast By End user
  • 7.8. Mexico In Vitro Fertilization Market Outlook
  • 7.8.1. Market Size By Value
  • 7.8.2. Market Size and Forecast By Cycle
  • 7.8.3. Market Size and Forecast By Conventional IVF
  • 7.8.4. Market Size and Forecast By End user
  • 8. Europe In Vitro Fertilization Market Outlook
  • 8.1. Market Size By Value
  • 8.2. Market Share By Country
  • 8.3. Market Size and Forecast, By Cycle
  • 8.4. Market Size and Forecast, By Conventional IVF
  • 8.5. Market Size and Forecast, By End user
  • 8.6. Germany In Vitro Fertilization Market Outlook
  • 8.6.1. Market Size By Value
  • 8.6.2. Market Size and Forecast By Cycle
  • 8.6.3. Market Size and Forecast By Conventional IVF
  • 8.6.4. Market Size and Forecast By End user
  • 8.7. United Kingdom In Vitro Fertilization Market Outlook
  • 8.7.1. Market Size By Value
  • 8.7.2. Market Size and Forecast By Cycle
  • 8.7.3. Market Size and Forecast By Conventional IVF
  • 8.7.4. Market Size and Forecast By End user
  • 8.8. France In Vitro Fertilization Market Outlook
  • 8.8.1. Market Size By Value
  • 8.8.2. Market Size and Forecast By Cycle
  • 8.8.3. Market Size and Forecast By Conventional IVF
  • 8.8.4. Market Size and Forecast By End user
  • 8.9. Italy In Vitro Fertilization Market Outlook
  • 8.9.1. Market Size By Value
  • 8.9.2. Market Size and Forecast By Cycle
  • 8.9.3. Market Size and Forecast By Conventional IVF
  • 8.9.4. Market Size and Forecast By End user
  • 8.10. Spain In Vitro Fertilization Market Outlook
  • 8.10.1. Market Size By Value
  • 8.10.2. Market Size and Forecast By Cycle
  • 8.10.3. Market Size and Forecast By Conventional IVF
  • 8.10.4. Market Size and Forecast By End user
  • 8.11. Russia In Vitro Fertilization Market Outlook
  • 8.11.1. Market Size By Value
  • 8.11.2. Market Size and Forecast By Cycle
  • 8.11.3. Market Size and Forecast By Conventional IVF
  • 8.11.4. Market Size and Forecast By End user
  • 9. Asia-Pacific In Vitro Fertilization Market Outlook
  • 9.1. Market Size By Value
  • 9.2. Market Share By Country
  • 9.3. Market Size and Forecast, By Cycle
  • 9.4. Market Size and Forecast, By Conventional IVF
  • 9.5. Market Size and Forecast, By End user
  • 9.6. China In Vitro Fertilization Market Outlook
  • 9.6.1. Market Size By Value
  • 9.6.2. Market Size and Forecast By Cycle
  • 9.6.3. Market Size and Forecast By Conventional IVF
  • 9.6.4. Market Size and Forecast By End user
  • 9.7. Japan In Vitro Fertilization Market Outlook
  • 9.7.1. Market Size By Value
  • 9.7.2. Market Size and Forecast By Cycle
  • 9.7.3. Market Size and Forecast By Conventional IVF
  • 9.7.4. Market Size and Forecast By End user
  • 9.8. India In Vitro Fertilization Market Outlook
  • 9.8.1. Market Size By Value
  • 9.8.2. Market Size and Forecast By Cycle
  • 9.8.3. Market Size and Forecast By Conventional IVF
  • 9.8.4. Market Size and Forecast By End user
  • 9.9. Australia In Vitro Fertilization Market Outlook
  • 9.9.1. Market Size By Value
  • 9.9.2. Market Size and Forecast By Cycle
  • 9.9.3. Market Size and Forecast By Conventional IVF
  • 9.9.4. Market Size and Forecast By End user
  • 9.10. South Korea In Vitro Fertilization Market Outlook
  • 9.10.1. Market Size By Value
  • 9.10.2. Market Size and Forecast By Cycle
  • 9.10.3. Market Size and Forecast By Conventional IVF
  • 9.10.4. Market Size and Forecast By End user
  • 10. South America In Vitro Fertilization Market Outlook
  • 10.1. Market Size By Value
  • 10.2. Market Share By Country
  • 10.3. Market Size and Forecast, By Cycle
  • 10.4. Market Size and Forecast, By Conventional IVF
  • 10.5. Market Size and Forecast, By End user
  • 10.6. Brazil In Vitro Fertilization Market Outlook
  • 10.6.1. Market Size By Value
  • 10.6.2. Market Size and Forecast By Cycle
  • 10.6.3. Market Size and Forecast By Conventional IVF
  • 10.6.4. Market Size and Forecast By End user
  • 10.7. Argentina In Vitro Fertilization Market Outlook
  • 10.7.1. Market Size By Value
  • 10.7.2. Market Size and Forecast By Cycle
  • 10.7.3. Market Size and Forecast By Conventional IVF
  • 10.7.4. Market Size and Forecast By End user
  • 10.8. Columbia In Vitro Fertilization Market Outlook
  • 10.8.1. Market Size By Value
  • 10.8.2. Market Size and Forecast By Cycle
  • 10.8.3. Market Size and Forecast By Conventional IVF
  • 10.8.4. Market Size and Forecast By End user
  • 11. Middle East & Africa In Vitro Fertilization Market Outlook
  • 11.1. Market Size By Value
  • 11.2. Market Share By Country
  • 11.3. Market Size and Forecast, By Cycle
  • 11.4. Market Size and Forecast, By Conventional IVF
  • 11.5. Market Size and Forecast, By End user
  • 11.6. UAE In Vitro Fertilization Market Outlook
  • 11.6.1. Market Size By Value
  • 11.6.2. Market Size and Forecast By Cycle
  • 11.6.3. Market Size and Forecast By Conventional IVF
  • 11.6.4. Market Size and Forecast By End user
  • 11.7. Saudi Arabia In Vitro Fertilization Market Outlook
  • 11.7.1. Market Size By Value
  • 11.7.2. Market Size and Forecast By Cycle
  • 11.7.3. Market Size and Forecast By Conventional IVF
  • 11.7.4. Market Size and Forecast By End user
  • 11.8. South Africa In Vitro Fertilization Market Outlook
  • 11.8.1. Market Size By Value
  • 11.8.2. Market Size and Forecast By Cycle
  • 11.8.3. Market Size and Forecast By Conventional IVF
  • 11.8.4. Market Size and Forecast By End user
  • 12. Competitive Landscape
  • 12.1. Competitive Dashboard
  • 12.2. Business Strategies Adopted by Key Players
  • 12.3. Key Players Market Share Insights and Analysis, 2022
  • 12.4. Key Players Market Positioning Matrix
  • 12.5. Porter's Five Forces
  • 12.6. Company Profile
  • 12.6.1. Thermo Fisher Scientific Inc.
  • 12.6.1.1. Company Snapshot
  • 12.6.1.2. Company Overview
  • 12.6.1.3. Financial Highlights
  • 12.6.1.4. Geographic Insights
  • 12.6.1.5. Business Segment & Performance
  • 12.6.1.6. Product Portfolio
  • 12.6.1.7. Key Executives
  • 12.6.1.8. Strategic Moves & Developments
  • 12.6.2. Vitrolife AB
  • 12.6.3. Fujifilm Holdings Corporation
  • 12.6.4. Merck KGaA
  • 12.6.5. The Cooper Companies, Inc.
  • 12.6.6. Esco Micro Pte. Ltd.
  • 12.6.7. Genea Limited
  • 12.6.8. Ferring Pharmaceuticals
  • 12.6.9. Hamilton Thorne Inc.
  • 12.6.10. Carl Zeiss AG,
  • 12.6.11. Cook Group Incorporated
  • 12.6.12. Kitazato Corporation
  • 12.6.13. Inser
  • 13. Strategic Recommendations
  • 14. Annexure
  • 14.1. FAQ`s
  • 14.2. Notes
  • 14.3. Related Reports
  • 15. Disclaimer

Table 1: Global In Vitro Fertilization Market Snapshot, By Segmentation (2023 & 2029) (in USD Billion)
Table 2: Influencing Factors for In Vitro Fertilization Market, 2023
Table 3: Top 10 Counties Economic Snapshot 2022
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global In Vitro Fertilization Market Size and Forecast, By Geography (2018 to 2029F) (In USD Billion)
Table 7: Global In Vitro Fertilization Market Size and Forecast, By Cycle (2018 to 2029F) (In USD Billion)
Table 8: Global In Vitro Fertilization Market Size and Forecast, By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 9: Global In Vitro Fertilization Market Size and Forecast, By End user (2018 to 2029F) (In USD Billion)
Table 10: North America In Vitro Fertilization Market Size and Forecast, By Cycle (2018 to 2029F) (In USD Billion)
Table 11: North America In Vitro Fertilization Market Size and Forecast, By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 12: North America In Vitro Fertilization Market Size and Forecast, By End user (2018 to 2029F) (In USD Billion)
Table 13: United States In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 14: United States In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 15: United States In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 16: Canada In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 17: Canada In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 18: Canada In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 19: Mexico In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 20: Mexico In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 21: Mexico In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 22: Europe In Vitro Fertilization Market Size and Forecast, By Cycle (2018 to 2029F) (In USD Billion)
Table 23: Europe In Vitro Fertilization Market Size and Forecast, By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 24: Europe In Vitro Fertilization Market Size and Forecast, By End user (2018 to 2029F) (In USD Billion)
Table 25: Germany In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 26: Germany In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 27: Germany In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 28: United Kingdom In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 29: United Kingdom In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 30: United Kingdom In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 31: France In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 32: France In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 33: France In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 34: Italy In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 35: Italy In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 36: Italy In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 37: Spain In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 38: Spain In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 39: Spain In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 40: Russia In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 41: Russia In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 42: Russia In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 43: Asia-Pacific In Vitro Fertilization Market Size and Forecast, By Cycle (2018 to 2029F) (In USD Billion)
Table 44: Asia-Pacific In Vitro Fertilization Market Size and Forecast, By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 45: Asia-Pacific In Vitro Fertilization Market Size and Forecast, By End user (2018 to 2029F) (In USD Billion)
Table 46: China In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 47: China In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 48: China In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 49: Japan In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 50: Japan In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 51: Japan In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 52: India In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 53: India In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 54: India In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 55: Australia In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 56: Australia In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 57: Australia In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 58: South Korea In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 59: South Korea In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 60: South Korea In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 61: South America In Vitro Fertilization Market Size and Forecast, By Cycle (2018 to 2029F) (In USD Billion)
Table 62: South America In Vitro Fertilization Market Size and Forecast, By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 63: South America In Vitro Fertilization Market Size and Forecast, By End user (2018 to 2029F) (In USD Billion)
Table 64: Brazil In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 65: Brazil In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 66: Brazil In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 67: Argentina In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 68: Argentina In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 69: Argentina In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 70: Colombia In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 71: Colombia In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 72: Colombia In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 73: Middle East & Africa In Vitro Fertilization Market Size and Forecast, By Cycle (2018 to 2029F) (In USD Billion)
Table 74: Middle East & Africa In Vitro Fertilization Market Size and Forecast, By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 75: Middle East & Africa In Vitro Fertilization Market Size and Forecast, By End user (2018 to 2029F) (In USD Billion)
Table 76: United Arab Emirates In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 77: United Arab Emirates In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 78: United Arab Emirates In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 79: Saudi Arabia In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 80: Saudi Arabia In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 81: Saudi Arabia In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)
Table 82: South Africa In Vitro Fertilization Market Size and Forecast By Cycle (2018 to 2029F) (In USD Billion)
Table 83: South Africa In Vitro Fertilization Market Size and Forecast By Conventional IVF (2018 to 2029F) (In USD Billion)
Table 84: South Africa In Vitro Fertilization Market Size and Forecast By End user (2018 to 2029F) (In USD Billion)

Figure 1: Global In Vitro Fertilization Market Size (USD Billion) By Region, 2023 & 2029
Figure 2: Market attractiveness Index, By Region 2029
Figure 3: Market attractiveness Index, By Segment 2029
Figure 4: Global In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 5: Global In Vitro Fertilization Market Share By Region (2023)
Figure 6: North America In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 7: North America In Vitro Fertilization Market Share By Country (2023)
Figure 8: US In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 9: Canada In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 10: Mexico In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 11: Europe In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 12: Europe In Vitro Fertilization Market Share By Country (2023)
Figure 13: Germany In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 14: UK In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 15: France In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 16: Italy In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 17: Spain In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 18: Russia In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 19: Asia-Pacific In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 20: Asia-Pacific In Vitro Fertilization Market Share By Country (2023)
Figure 21: China In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 22: Japan In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 23: India In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 24: Australia In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 25: South Korea In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 26: South America In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 27: South America In Vitro Fertilization Market Share By Country (2023)
Figure 28: Brazil In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 29: Argentina In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 30: Columbia In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 31: Middle East & Africa In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 32: Middle East & Africa In Vitro Fertilization Market Share By Country (2023)
Figure 33: UAE In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 34: Saudi Arabia In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 35: South Africa In Vitro Fertilization Market Size By Value (2018, 2023 & 2029F) (in USD Billion)
Figure 36: Competitive Dashboard of top 5 players, 2023
Figure 37: Market Share insights of key players, 2023
Figure 38: Porter's Five Forces of Global In Vitro Fertilization Market

IVF (in-vitro fertilization) Market Research FAQs

IVF is a type of assisted reproductive technology (ART) where fertilization occurs outside the body in a laboratory dish. It involves retrieving eggs from a woman's ovaries, fertilizing them with sperm in a laboratory, and transferring the resulting embryos back into the woman's uterus.

IVF is used to treat infertility in couples who have difficulty conceiving naturally due to various reasons, including issues with ovulation, sperm quality, fallopian tube blockages, or unexplained infertility.

IVF has become increasingly prevalent worldwide, with millions of cycles performed each year. The prevalence varies by region, with higher rates in developed countries where access to fertility treatment is more widespread.

Factors contributing to the growth of the global IVF market include increasing infertility rates due to factors such as delayed childbearing, lifestyle changes, and environmental factors, as well as advancements in technology, rising awareness about fertility treatment options, and supportive government policies or insurance coverage in some regions.

The key components of the IVF market include fertility clinics, pharmaceutical companies supplying fertility drugs, medical device manufacturers producing IVF equipment and consumables, and ancillary services such as genetic testing, counseling, and cryopreservation.

Challenges facing the IVF market include the high cost of treatment, lack of insurance coverage in many regions, ethical considerations related to practices such as egg donation and surrogacy, variability in success rates among clinics, and the emotional toll of infertility treatment on patients.

Emerging trends in the IVF market include the increasing use of advanced technologies such as time-lapse embryo imaging, preimplantation genetic testing (PGT), and mitochondrial replacement therapy (MRT), as well as the growing popularity of fertility preservation for elective reasons or medical indications.
Logo

Global IVF (in-vitro fertilization) Market Outlook, 2029

Contact usWe are friendly and approachable, give us a call.